logo

For the Inventor, By the Inventor

Copenhagen, Denmark

Galecto Biotech Ab

Calculating rank
USPTO Granted Patents = 29

% Expired Patents = 17.2



Trademarks = 1

Forward Citations = 75

Loading Chart...
Loading Chart...

21 inventors (with patents filed for the assignee):

goldMedal Ulf Nilsson (17 out of 21 patents)

silverMedal Fredrik Zetterberg (17 out of 17 patents)

bronzeMedal Hakon Leffler (15 out of 17 patents)

4.  Thomas Brimert (7 out of 10 patents)

5.  Anders Pedersen (6 out of 21 patents)

6.  Richard Johnsson (6 out of 6 patents)

7.  Kristoffer Peterson (4 out of 4 patents)

8.  Lise Gravelle (3 out of 3 patents)

9.  Tariq Sethi (3 out of 3 patents)

10.  Alison Mackinnon (3 out of 3 patents)

11.  Karl Jansson (3 out of 4 patents)

12.  Hans Schambye (2 out of 2 patents)

13.  Paul Ford (1 out of 1 patent)

14.  Neil Cowan Henderson (1 out of 7 patents)

15.  Priya Verma (1 out of 1 patent)


Core Competencies:
Galactoside Inhibitor
Galectin-3
Pulmonary Fibrosis
Alpha-D-Galactoside
Polymorphic Forms
Hybrid Inhibitors
Synthesis
Inhibitors

29 patents:

1. 12774298 - Amorphous form of 5-Bromopyridin-3-yl 3-deoxy-3-[4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl]-1-thio-alpha-d-galactopyranoside (2026-10-27),
2. 12497428 - Galactoside inhibitor of galectins (2025-12-16),
3. 12441755 - Galactoside inhibitor of galectins (2025-10-14),
4. 12441754 - Galactoside inhibitor of galectins (2025-10-14),
5. 12410207 - Galactoside inhibitor of galectins (2025-09-09),
6. 11939349 - Galactoside inhibitor of galectins (2024-03-26),
7. 11919921 - Galactoside inhibitor of galectins (2024-03-05),
8. 11827666 - Galactoside inhibitor of galectins (2023-11-28),
9. 11447517 - Galactoside inhibitor of galectins (2022-09-20),
10. 11406655 - Once-daily treatment of pulmonary fibrosis (2022-08-09),
11. 11377464 - Galactoside inhibitor of galectins (2022-07-05),
12. 11046725 - Galactoside inhibitor of galectins (2021-06-29),
13. 10988502 - Alpha-D-galactoside inhibitors of galectins (2021-04-27),
14. 10889610 - Alpha-D-galactoside inhibitors of galectins (2021-01-12),
15. 10800804 - Hybrid galactoside inhibitor of galectins (2020-10-13),
Company Overview
Galecto Biotech Ab is a biotechnology company based in Copenhagen, Denmark, focused on developing innovative therapies for fibrotic diseases and cancer. The company specializes in the research and development of small molecule drugs that target galectin proteins, which play a crucial role in various pathological processes, including inflammation and tissue remodeling. Through its advanced scientific approach, Galecto aims to address significant unmet medical needs and improve patient outcomes in challenging therapeutic areas.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Nov 10 2026

Galecto Biotech Ab USPTO Patent Assignee Logo
29 Patents

#15 in Copenhagen

#107 in Denmark

#22,622 in the World

Copenhagen, DK
Copenhagen, Denmark

Galecto Biotech Ab

Forward Citations = 75

21 inventors:

goldMedal Ulf Nilsson (17 out of 21 patents)

silverMedal Fredrik Zetterberg (17 out of 17 patents)

bronzeMedal Hakon Leffler (15 out of 17 patents)

4.  Thomas Brimert (7 out of 10 patents)

5.  Anders Pedersen (6 out of 21 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Galecto Biotech Ab. Retrieved from https://idiyas.com/company/galecto-biotech-ab

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…